Children diagnosed with attention-deficit/hyperactivity disorder (ADHD)—especially those treated long term with Ritalin—may face increased risks of becoming overweight and experiencing shorter stature later in life, a recent large-scale research suggests.
The study examined health data from about 35,000 young people in South Korea over roughly 12 years. Researchers tracked children ages 6 to 19 who received an ADHD diagnosis between 2008 and 2013, following them until they reached adulthood.
Weight and Stature Changes
The findings, published in JAMA Network Open, showed that children with ADHD had a higher average body mass index than children without ADHD, with average BMIs of 24.3 versus 23.3.
Children who used methylphenidate, the generic name for Ritalin, for more than a year had an even greater likelihood of being overweight or obese, with a 60 percent higher odds compared with their peers without ADHD.
Notably, the prevalence of severe obesity—a BMI of 30 or higher—was nearly twice as high among children with ADHD on long-term Ritalin therapy, rising from 9.3 percent in controls to 16.1 percent in the medication group.
The study also uncovered a subtle trend toward shorter adult height among children taking extended Ritalin treatment.
The average height difference was small: about 0.6 centimeters (about a quarter inch) for females and about 0.1 centimeters (about 0.03 inch) for males.
Researchers speculate that Ritalin’s appetite-suppressing effects and a possible disruption of growth hormone release during sleep could help explain these findings.
The study had several important limitations that may affect the validity of the findings. Researchers could not fully control confounding factors such as parents’ BMI and height, pubertal and menstrual status, genetics, nutrition, sleep quality, heart rate, and growth hormone levels—all of which can significantly influence weight and height outcomes.
Additionally, since the study was conducted in an Asian population, racial differences may affect how broadly the findings apply.
The study also lacked detailed data on lifestyle factors such as diet, physical activity, and sleep patterns. As a result, researchers couldn’t determine whether the obesity risk stems primarily from ADHD itself, the medication, their interaction, or lifestyle changes related to either factor.
Findings Warrant Attention
Although the advantages of methylphenidate use in ADHD are well recognized, the study authors noted, the findings underscore the importance of careful clinical judgment that takes into account possible long-term health effects such as obesity and reduced height.
Dr. Nona Kocher, a board-certified psychiatrist at Quintessence Psychiatry in Miami who was not involved in the study, told The Epoch Times that the findings warrant attention but shouldn’t discourage appropriate treatment.
“Ritalin clearly helps many children manage ADHD, which can improve school [performance], social life, and overall well-being,” she said. “The small changes in height and weight are worth noting, but they don’t outweigh the benefits for most kids.”
Kocher noted that a height change under 1 centimeter isn’t considered a serious issue, and emphasized that untreated ADHD can lead to struggles with learning, relationships, and self-esteem that have their own long-term consequences.
She added that families and doctors can discuss different dosing strategies or alternative medications if there are concerns about growth or weight.
“Keeping an eye on growth, weight, diet, and exercise can help address any small long-term effects while still managing ADHD effectively,” Kocher said.
The study authors also noted that future research should aim to identify modifiable risk factors, improve treatment approaches, and establish clearer guidelines for tracking growth and metabolic health in people with ADHD.